March 28 Biogen Idec Inc has won U.S.
approval for its long-acting hemophilia B treatment Alprolix,
the U.S. Food and Drug Administration said on Friday.
Hemophilia B is a rare, inherited disorder in which a
person's blood does not clot properly, potentially leading to
prolonged bleeding and bruising. It affects about 4,000 people
in the United States and 25,000 worldwide.
Alprolix is a bioengineered version of the blood coagulation
factor IX, a protein needed for normal blood clotting. Biogen is
developing the drug in partnership with Swedish Orphan Biovitrum
AB. It received approval in Canada a week ago.
(Reporting by Toni Clarke in Washington; Editing by David